Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (141-150 of 192) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|September 10, 2011
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trialMichel Ducreux, David Malka, Jean Mendiboure, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trialLoic Verlingue, David Malka, Adrien Allorant, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2023
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trialDavid Malka, Benjamin Verret, Matthieu Faron, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2018
Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130]Loic Verlingue, David Malka, Adrien Allorant, et al.
Clinical Kidney Journal|February 13, 2019
Renal toxicities associated with pembrolizumabHassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 TrialLaetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studiesJulien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.
International Journal of Cancer|December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO studyMarie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2020
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancerPatricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, et al.
Pageof 20

Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|September 10, 2011
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trialMichel Ducreux, David Malka, Jean Mendiboure, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trialLoic Verlingue, David Malka, Adrien Allorant, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2023
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trialDavid Malka, Benjamin Verret, Matthieu Faron, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2018
Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130]Loic Verlingue, David Malka, Adrien Allorant, et al.
Clinical Kidney Journal|February 13, 2019
Renal toxicities associated with pembrolizumabHassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 TrialLaetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studiesJulien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.
International Journal of Cancer|December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO studyMarie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2020
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancerPatricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, et al.
Pageof 20